ELAB
Price
$4.97
Change
+$0.08 (+1.64%)
Updated
Nov 19 closing price
Capitalization
3.7M
Intraday BUY SELL Signals
TBPH
Price
$17.73
Change
-$0.76 (-4.11%)
Updated
Nov 19, 04:59 PM (EDT)
Capitalization
898.42M
102 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ELAB vs TBPH

Header iconELAB vs TBPH Comparison
Open Charts ELAB vs TBPHBanner chart's image
PMGC Holdings
Price$4.97
Change+$0.08 (+1.64%)
Volume$78.96K
Capitalization3.7M
Theravance Biopharma
Price$17.73
Change-$0.76 (-4.11%)
Volume$6.27K
Capitalization898.42M
ELAB vs TBPH Comparison Chart in %
ELAB
Daily Signal:
Gain/Loss:
TBPH
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ELAB vs. TBPH commentary
Nov 20, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ELAB is a Hold and TBPH is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 20, 2025
Stock price -- (ELAB: $4.97 vs. TBPH: $17.73)
Brand notoriety: ELAB and TBPH are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ELAB: 10% vs. TBPH: 138%
Market capitalization -- ELAB: $3.7M vs. TBPH: $898.42M
ELAB [@Biotechnology] is valued at $3.7M. TBPH’s [@Biotechnology] market capitalization is $898.42M. The market cap for tickers in the [@Biotechnology] industry ranges from $106.82B to $0. The average market capitalization across the [@Biotechnology] industry is $2.12B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ELAB’s FA Score shows that 1 FA rating(s) are green whileTBPH’s FA Score has 0 green FA rating(s).

  • ELAB’s FA Score: 1 green, 4 red.
  • TBPH’s FA Score: 0 green, 5 red.
According to our system of comparison, both ELAB and TBPH are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ELAB’s TA Score shows that 4 TA indicator(s) are bullish while TBPH’s TA Score has 4 bullish TA indicator(s).

  • ELAB’s TA Score: 4 bullish, 6 bearish.
  • TBPH’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, TBPH is a better buy in the short-term than ELAB.

Price Growth

ELAB (@Biotechnology) experienced а -12.10% price change this week, while TBPH (@Biotechnology) price change was -0.28% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.19%. For the same industry, the average monthly price growth was -5.74%, and the average quarterly price growth was +63.93%.

Reported Earning Dates

TBPH is expected to report earnings on Mar 02, 2026.

Industries' Descriptions

@Biotechnology (-2.19% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TBPH($898M) has a higher market cap than ELAB($3.7M). TBPH has higher P/E ratio than ELAB: TBPH (31.11) vs ELAB (0.01). TBPH YTD gains are higher at: 88.417 vs. ELAB (-91.133). TBPH has higher annual earnings (EBITDA): 46.1M vs. ELAB (-4.37M). TBPH has more cash in the bank: 339M vs. ELAB (6.31M). ELAB has less debt than TBPH: ELAB (103K) vs TBPH (46.5M). TBPH has higher revenues than ELAB: TBPH (77.2M) vs ELAB (0).
ELABTBPHELAB / TBPH
Capitalization3.7M898M0%
EBITDA-4.37M46.1M-9%
Gain YTD-91.13388.417-103%
P/E Ratio0.0131.110%
Revenue077.2M-
Total Cash6.31M339M2%
Total Debt103K46.5M0%
FUNDAMENTALS RATINGS
TBPH: Fundamental Ratings
TBPH
OUTLOOK RATING
1..100
26
VALUATION
overvalued / fair valued / undervalued
1..100
75
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
77
PRICE GROWTH RATING
1..100
36
P/E GROWTH RATING
1..100
87
SEASONALITY SCORE
1..100
75

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ELABTBPH
RSI
ODDS (%)
Bearish Trend 6 days ago
90%
Bearish Trend 2 days ago
81%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
73%
Bearish Trend 2 days ago
76%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 2 days ago
79%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 2 days ago
68%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 2 days ago
65%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 9 days ago
86%
Bullish Trend 2 days ago
79%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 13 days ago
70%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
86%
Bearish Trend 2 days ago
84%
Aroon
ODDS (%)
Bullish Trend 1 day ago
75%
Bullish Trend 2 days ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
ELAB
Daily Signal:
Gain/Loss:
TBPH
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BBT24.640.12
+0.49%
Beacon Financial Corporation
XRTX0.55-0.01
-1.02%
XORTX Therapeutics
CLX98.43-1.71
-1.71%
Clorox Company
MDIA0.95-0.02
-1.87%
Mediaco Holding
ENGN6.75-0.13
-1.89%
enGene Holdings

ELAB and

Correlation & Price change

A.I.dvisor tells us that ELAB and LXRX have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ELAB and LXRX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ELAB
1D Price
Change %
ELAB100%
+1.74%
LXRX - ELAB
25%
Poorly correlated
-1.36%
MTNB - ELAB
24%
Poorly correlated
-31.52%
EDSA - ELAB
23%
Poorly correlated
+0.57%
TGTX - ELAB
21%
Poorly correlated
-2.82%
TBPH - ELAB
21%
Poorly correlated
-4.11%
More

TBPH and

Correlation & Price change

A.I.dvisor indicates that over the last year, TBPH has been loosely correlated with KYMR. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if TBPH jumps, then KYMR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TBPH
1D Price
Change %
TBPH100%
-4.11%
KYMR - TBPH
48%
Loosely correlated
+0.95%
VERA - TBPH
36%
Loosely correlated
-1.25%
AXON - TBPH
34%
Loosely correlated
-0.50%
VYGR - TBPH
34%
Loosely correlated
-2.69%
ARRY - TBPH
34%
Loosely correlated
-2.47%
More